SOURCE: Trimedyne, Inc.

March 13, 2007 09:30 ET

Trimedyne's Chairman Interviewed by WallSt.net

LAKE FOREST, CA -- (MARKET WIRE) -- March 13, 2007 -- TRIMEDYNE, INC. (OTCBB: TMED) today announced its chairman, Dr. Marvin P. Loeb, was interviewed live by WallSt.net. The audio interview will be available at http://www.wallst.net/audio/audio.asp?symbol=TMED&id=3135.

Dr. Loeb discussed the Company's recently announced, worldwide marketing alliance with Boston Scientific and Lumenis, Ltd., who will distribute Trimedyne's new Side Firing Laser Fiber as an accessory to Lumenis' Holmium Lasers for the treatment of enlarged prostates in men. About 50% of men over age 55 suffer from an enlarged prostate, an estimated $700 million annual market. Dr. Loeb also described the $600 million potential market for the Company's outpatient laser procedures to treat herniated or ruptured discs in the spine, its four consecutive years of profitability and its current financial condition.

Commenting on the upcoming interview, Dr. Loeb said, "We are pleased that WallSt.net is featuring Trimedyne on their website and alerting the investment community on the potential for growth of Trimedyne's outpatient procedures for treating enlarged prostates and herniated or ruptured discs in the spine."

About WallSt.net

WallSt.net is an online, market news provider that brings current news and market insight to investors and features one-on-one live interaction with executives of promising, publicly-held companies.

About Trimedyne, Inc.

Trimedyne is a leading manufacturer of proprietary medical lasers and patented fiber optic devices for performing a variety of minimally invasive procedures as a less traumatic, lower cost alternative to traditional surgery. For additional information, visit Trimedyne's website at http://www.trimedyne.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release and the above mentioned interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-K-SB and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

Contact Information